Cytokinetics (CYTK) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Cytokinetics (CYTK) over the last 14 years, with Q4 2024 value amounting to $26.2 million.
- Cytokinetics' Share-based Compensation rose 3470.52% to $26.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $97.8 million, marking a year-over-year increase of 3575.5%. This contributed to the annual value of $97.8 million for FY2024, which is 3576.63% up from last year.
- According to the latest figures from Q4 2024, Cytokinetics' Share-based Compensation is $26.2 million, which was up 3470.52% from $25.4 million recorded in Q3 2024.
- In the past 5 years, Cytokinetics' Share-based Compensation registered a high of $26.2 million during Q4 2024, and its lowest value of $3.5 million during Q1 2020.
- For the 5-year period, Cytokinetics' Share-based Compensation averaged around $13.1 million, with its median value being $12.7 million (2022).
- Per our database at Business Quant, Cytokinetics' Share-based Compensation soared by 10046.19% in 2022 and then surged by 3189.42% in 2024.
- Over the past 5 years, Cytokinetics' Share-based Compensation (Quarter) stood at $4.9 million in 2020, then skyrocketed by 37.61% to $6.7 million in 2021, then soared by 100.46% to $13.5 million in 2022, then surged by 44.85% to $19.5 million in 2023, then soared by 34.71% to $26.2 million in 2024.
- Its last three reported values are $26.2 million in Q4 2024, $25.4 million for Q3 2024, and $24.6 million during Q2 2024.